NFKB1 and Insulin resistance: Similarly to insulin and GLP-1RA, metformin has been suggested to improve chronic inflammation indirectly, via insulin resistance and hyperglycemia improvement, but also directly by inhibiting NF-κB via AMP-activated protein kinase (AMPK)-dependent and independent pathways (85–88).